An observational study in Axial Spondyloarthritis, sponsored by AbbVie. Terminated at 6 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-10-02.
Sponsored by AbbVie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Axial Spondyloarthritis with a site in Germany — 6 open to participants now, 9 under way, 1 of them phase 3. Axial Spondyloarthritis · Germany.
Among the 30 studies in Axial Spondyloarthritis with a site in Germany, this one is one of 4 that started in 2017, is one of 8 observational ones, and was the 13th registered.
187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.
Browse Axial Spondyloarthritis studies →6 of the 30 studies in Axial Spondyloarthritis with a site in Germany are open now. Recruiting first, the newest first:
Wuerzburg University Hospital · Sites in Germany
Ages 18+
UCB Biopharma SRL · Sites in Germany, United States, Bulgaria and 3 more countries
Ages 18+
UCB Biopharma SRL · Sites in Germany, United States, Canada and 2 more countries
Ages 18+ · Women only
Grey Wolf Therapeutics · Sites in Germany, Australia, Belgium and 3 more countries
Ages 18–65
University of Bonn · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 13 · Phase 4 2
First in 2005; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 180 across 61 observational studies indexed under Axial Spondyloarthritis.
Median enrollment 304 across the 22 interventional studies, 543 across the 8 observational. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 9 studies filed under Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
3 of the studies in Axial Spondyloarthritis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07561255Wuerzburg University HospitalExploratory Investigation of the Acceptance and Utility of 14-day Trial Periods and Application-related Outcome Measurement (AbEM) Within the Routine Prescription of the DiGA Axia. | 2026-12-31 |
| NCT07133633Merck Sharp & Dohme LLCA Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) | 2027-03-29 |
| NCT05094128AbbVieA Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Axial Spondyloarthritis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a non-interventional, longitudinal and non-confirmatory study to compare an active supervised training (AST) with standard of care (SOC) physiotherapy in patients with axial spondyloarthritis and stable response to adalimumab (HUMIRA®) with respect to health-related outcomes. The primary objective is the improvement in spinal mobility after a 6 month training program.
Treatment of axSpA patients with adalimumab (HUMIRA®) was according to the local adalimumab product label and local standard of care. AxSpA patients who responded to newly initialized adalimumab treatment based on physicians' decision, and who were eligible for active physiotherapy were enrolled in the study. Although this was a non-interventional study, participants were randomly assigned to receive either active supervised and standardized training physiotherapy or standard of care physiotherapy in order to provide adequate numbers of participants in each comparison group.
Participants who consented to participate in the study were observed for up to 12 months from Baseline (defined as the Randomization visit where participants were assigned to one of the two physiotherapy options).
Participants with axial spondyloarthritis who received Humira® per local product label at rheumatology centers in Germany.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive active supervised and standardized training (AST).
Behavioral: Active Supervised Training (AST)
Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive standard of care physiotherapy, according to the physiotherapist discretion.
Behavioral: Standard of Care (SOC) Physiotherapy
The active supervised and standardized training consisted of 24 units of exercise within 20 weeks performed in certified training centers and was focused on back fitness, core strengthening and patient engagement to treat back pain and functional impairment.
Standard of care physiotherapy as used in this study included active as well as passive training and massages according to the physiotherapist discretion.
Change Form Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Month 6
BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. The total BASMI score ranges from 0 to 10 reflecting mild to moderate disease activity and functional ability in the spinal column. The higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis
Time frame: Baseline and Month 6
Change Form Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Month 3
BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. The total BASMI score ranges from 0 to 10 reflecting mild to moderate disease activity and functional ability in the spinal column. The higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis.
Time frame: Baseline and Month 3
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
The Bath Ankylosing Spondylitis Functional Index (BASFI) is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities, each on a numeric rating scale (NRS) ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher score indicating more limitations.
Time frame: Baseline and Month 3
Change From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)
The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. The ASAS HI consists of 17 questions, each answered by the participant as agree (1) or disagree (0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, with a lower score indicating a better and a higher score indicating an inferior health status.
Time frame: Baseline and Month 3
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 where lower scores indicate less disease activity.
Time frame: Baseline and Month 3
Percentage of Participants Achieving a BASDAI 50 Response
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from baseline in BASDAI score.
Time frame: Month 3
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (C-reactive protein \[CRP\]) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."
Time frame: Baseline and Month 3
Percentage of Participants With ASDAS Inactive Disease
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease, defined as ASDAS \< 1.3, is reported.
Time frame: Month 3
Percentage of Participants With ASDAS Low Disease Activity
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS low disease activity, defined as ASDAS \< 2.1, is reported.
Time frame: Month 3
Percentage of Participants With ASDAS Moderate Disease Activity
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS moderate disease activity, defined as an ASDAS ≥ 1.3 to \< 2.1, is reported.
Time frame: Month 3
Percentage of Participants With ASDAS High Disease Activity
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with high disease activity, defined as an ASDAS ≥ 2.1 to \< 3.5, is reported.
Time frame: Month 3
Percentage of Participants With ASDAS Very High Disease Activity
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with very high disease activity, defined as an ASDAS ≥ 3.5, is reported.
Time frame: Month 3
Percentage of Participants Achieving ASDAS Major Improvement
ASDAS Major Improvement is defined as a change from Baseline ≥ 2.0. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."
Time frame: Baseline and Month 3
Percentage of Participants Achieving ASDAS Clinically Important Improvement
ASDAS clinically important improvement is defined as a change from Baseline ≥ 1.1. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."
Time frame: Baseline and Month 3
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response
ASAS20 response was defined as improvement of ≥ 20% relative to Baseline and absolute improvement of ≥ 1 unit (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 unit) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Baseline and Month 3
Percentage of Participants Achieving an ASAS 40 Response
ASAS40 response was defined as improvement of ≥ 40% relative to baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Baseline and Month 3
Percentage of Participants Achieving ASAS Partial Remission
ASAS partial remission is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Month 3
Change From Baseline in Patient's Global Assessment of Pain
The patient's global assessment of pain was assessed on a NRS from 0 (no pain) to 10 (pain as bad as it could be).
Time frame: Baseline and Month 3
Change From Baseline in Patient's Assessment of Total Back Pain
The patient's assessment of total back pain was assessed on a NRS from 0 (no pain) to 10 (most severe pain).
Time frame: Baseline and Month 3
Change From Baseline in Patient's Assessment of Nocturnal Back Pain
The patient's assessment of nocturnal back pain was assessed on a NRS from 0 (no pain) to 10 (most severe pain).
Time frame: Baseline and Month 3
Change From Baseline in Modified Work Ability Index (WAI)
This is used to assess participant's work ability.
Time frame: Baseline and Month 3
Change From Baseline in Fatigue
Fatigue was assessed as Question 1 of the BASDAI, on a NRS from 0 (none) to 10 (very severe).
Time frame: Baseline and Month 3
Change From Baseline in Severity and Duration of Morning Stiffness
Morning stiffness was measured as the mean of the 2 morning stiffness-related BASDAI NRS scores: Question 5: Level of morning stiffness assessed by the patient on a scale from 0 (none) to 10 (very severe), and Question 6: Duration of morning stiffness assessed by the patient on a scale from 0 (0 hours) to 10 (2 hours or more duration).
Time frame: Baseline and Month 3
Change From Baseline in Fear-Avoidance Belief Questionnaire Score (FABQ)
The FABQ measures patients' fear of pain and consequent avoidance of physical activity because of their fear. The questionnaire consists of 16 items in which a patient rates their agreement with each statement on a 7-point Likert scale, where 0 = completely disagree, 6 = completely agree. There is a maximum score of 96. A higher score indicates more strongly held fear avoidance beliefs.
Time frame: Baseline and Month 3
This study enrolled participants with axial spondyloarthritis (AS) at 7 study sites in Germany. Eligible participants were receiving treatment with adalimumab (HUMIRA®) based on therapist's decision and local label requirements, must have had a response to adalimumab and have been eligible for active physiotherapy.
| Milestone | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy | Not Randomized |
|---|---|---|---|
| Started | 4 | 3 | 10 |
| Completed | 0 | 0 | 0 |
| Not completed | 4 | 3 | 10 |
| Withdrew: Early termination | 4 | 3 | 10 |
BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. The total BASMI score ranges from 0 to 10 reflecting mild to moderate disease activity and functional ability in the spinal column. The higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis
No measurements were reported for this outcome.
BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. The total BASMI score ranges from 0 to 10 reflecting mild to moderate disease activity and functional ability in the spinal column. The higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis.
| scores on a scale | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Change Form Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Month 3 | 1.1 ± 0.4 | — |
The Bath Ankylosing Spondylitis Functional Index (BASFI) is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities, each on a numeric rating scale (NRS) ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher score indicating more limitations.
| scores on a scale | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) | -0.1 ± 0.1 | — |
The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. The ASAS HI consists of 17 questions, each answered by the participant as agree (1) or disagree (0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, with a lower score indicating a better and a higher score indicating an inferior health status.
| scores on a scale | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Change From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI) | 0.5 ± 0.7 | — |
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 where lower scores indicate less disease activity.
| scores on a scale | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | -0.4 ± 0.2 | — |
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from baseline in BASDAI score.
| percentage of participants | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Percentage of Participants Achieving a BASDAI 50 Response | 0.0 | — |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (C-reactive protein \[CRP\]) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."
| scores on a scale | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) | -0.3 ± 0.1 | — |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease, defined as ASDAS \< 1.3, is reported.
| percentage of participants | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Percentage of Participants With ASDAS Inactive Disease | 50.0 | — |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS low disease activity, defined as ASDAS \< 2.1, is reported.
| percentage of participants | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Percentage of Participants With ASDAS Low Disease Activity | 50.0 | — |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS moderate disease activity, defined as an ASDAS ≥ 1.3 to \< 2.1, is reported.
| percentage of participants | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Percentage of Participants With ASDAS Moderate Disease Activity | 0.0 | — |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with high disease activity, defined as an ASDAS ≥ 2.1 to \< 3.5, is reported.
| percentage of participants | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Percentage of Participants With ASDAS High Disease Activity | 50.0 | — |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with very high disease activity, defined as an ASDAS ≥ 3.5, is reported.
| percentage of participants | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Percentage of Participants With ASDAS Very High Disease Activity | 0.0 | — |
ASDAS Major Improvement is defined as a change from Baseline ≥ 2.0. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."
| percentage of participants | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Percentage of Participants Achieving ASDAS Major Improvement | 0.0 | — |
ASDAS clinically important improvement is defined as a change from Baseline ≥ 1.1. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."
| percentage of participants | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Percentage of Participants Achieving ASDAS Clinically Important Improvement | 0.0 | — |
ASAS20 response was defined as improvement of ≥ 20% relative to Baseline and absolute improvement of ≥ 1 unit (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 unit) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response | 0.0 | — |
ASAS40 response was defined as improvement of ≥ 40% relative to baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Percentage of Participants Achieving an ASAS 40 Response | 0.0 | — |
ASAS partial remission is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Percentage of Participants Achieving ASAS Partial Remission | 0.0 | — |
The patient's global assessment of pain was assessed on a NRS from 0 (no pain) to 10 (pain as bad as it could be).
| scores on a scale | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Change From Baseline in Patient's Global Assessment of Pain | -0.5 ± 0.7 | — |
The patient's assessment of total back pain was assessed on a NRS from 0 (no pain) to 10 (most severe pain).
| scores on a scale | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Change From Baseline in Patient's Assessment of Total Back Pain | 0.5 ± 0.7 | — |
The patient's assessment of nocturnal back pain was assessed on a NRS from 0 (no pain) to 10 (most severe pain).
| scores on a scale | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Change From Baseline in Patient's Assessment of Nocturnal Back Pain | -0.5 ± 0.7 | — |
This is used to assess participant's work ability.
No measurements were reported for this outcome.
Fatigue was assessed as Question 1 of the BASDAI, on a NRS from 0 (none) to 10 (very severe).
| scores on a scale | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Change From Baseline in Fatigue | -0.5 ± 0.7 | — |
Morning stiffness was measured as the mean of the 2 morning stiffness-related BASDAI NRS scores: Question 5: Level of morning stiffness assessed by the patient on a scale from 0 (none) to 10 (very severe), and Question 6: Duration of morning stiffness assessed by the patient on a scale from 0 (0 hours) to 10 (2 hours or more duration).
| scores on a scale | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy |
|---|---|---|
| Change From Baseline in Severity and Duration of Morning Stiffness | -1.5 ± 0.7 | — |
The FABQ measures patients' fear of pain and consequent avoidance of physical activity because of their fear. The questionnaire consists of 16 items in which a patient rates their agreement with each statement on a 7-point Likert scale, where 0 = completely disagree, 6 = completely agree. There is a maximum score of 96. A higher score indicates more strongly held fear avoidance beliefs.
No measurements were reported for this outcome.
Collected over Up to 3 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Supervised Training (AST) | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Standard of Care (SOC) Physiotherapy | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Not Randomized | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Event | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy | Not Randomized |
|---|---|---|---|
| Pulpitis dentalInfections and infestations | 0/4 | 1/3 | 0/10 |
| Urinary tract infectionInfections and infestations | 0/4 | 1/3 | 0/10 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/4 | 1/3 | 0/10 |
| Bone lesionMusculoskeletal and connective tissue disorders | 0/4 | 1/3 | 0/10 |
| Back painMusculoskeletal and connective tissue disorders | 1/4 | 0/3 | 0/10 |
| PsoriasisSkin and subcutaneous tissue disorders | 1/4 | 0/3 | 0/10 |
| Axial spondyloarthritisMusculoskeletal and connective tissue disorders | 0/4 | 0/3 | 1/10 |
All randomized participants
| Age, Continuous(years) | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy | Total |
|---|---|---|---|
| Median | 52 (37 to 66) | 31 (30 to 43) | 38 (30 to 66) |
| Sex: Female, Male(Participants) | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy | Total |
|---|---|---|---|
| Female | 2 | 1 | 3 |
| Male | 2 | 2 | 4 |
| Race and Ethnicity Not Collected(Participants) | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Bath Ankylosing Spondylitis Metrology Index (BASMI)(units on a scale) | Active Supervised Training (AST) | Standard of Care (SOC) Physiotherapy | Total |
|---|---|---|---|
| Mean | 2.9 ± 3.3 | 2.2 ± 0.8 | 2.6 ± 2.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Dec 2017 to primary completion in Sep 2018, 9 months.
Results were first posted in Oct 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.